Submit Manuscript Now
Current issue Archive Authors Profile
Research Articles Issue 1 · 2022 · pp. 123–129 · Issue page

SLOW ONSET TYPE 1 DIABETES ASSOCIATED WITH PREGNANCY: A CASE REPORT

AN
Ana-Maria CAȘLATOI1
EL
Elena Georgiana BERNEA2
DE
Denisa Isabella TĂNASIE3
DR
Dragoș Eugen GEORGESCU4
CR
Cristian GUJA5
DO
Doina-Andrada MIHAI6
CO
Constantin IONESCU-TÎRGOVIȘTE7
1 „N. Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest
2 University of Medicine and Pharmacy “Carol Davila”, Bucharest
3 National Institute of Endocrinology C.I.Parhon
4 University of Medicine and Pharmacy “Carol Davila”, Bucharest, ,,Dr I Cantacuzino” Hospital Bucharest
5 „N. Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest University of Medicine and Pharmacy “Carol Davila”, Bucharest
6 „N. Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest
7 „N. Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest
DOI https://doi.org/10.38173/RST.2022.23.1.14:123-129
Received 11 December 2021
Revised 28 January 2022
Accepted 15 February 2022
Available Online 15 March 2022
Abstract
GESTATIONAL DIABETES MELLITUS (GDM) IS DEFINED AS ANY GLUCOSE INTOLERANCE WITH FIRST RECOGNITION DURING PREGNANCY AND IT CAN BE REVELATORY OF UNDERLYING BETA - CELL DYSFUNCTION, WHICH CONFERS AN INCREASED RISK FOR LATER DEVELOPMENT OF DIABETES, BOTH TYPE 1 DIABETES (T1D M) AND TY PE 2 DIABETES (T2DM), THE LAST BEING THE MOST COMMON. A SUBGROUP OF PATIENTS WITH GDM, ESPECIALLY THOSE WITH AUTOANTIBODY POSITIVITY DURING AND AFTER PREGNANCY, MAY EVOLVE, OFTEN SEVERAL YEARS AFTER PREGNANCY, INTO CASES OF LATENT A UTOIMMUNE DIABE TES OF AD ULTHOOD (LADA), THE ‘’SLOWLY PROGRESSIVE AUTOIMMUNE DIABETES”. WE REPORT THE CASE OF A 29 - YEAR-OLD CAUCASIAN WOMAN, WHO FIRST PRESENTED TO OUR HOSPITAL IN OCTOBER 2014 FOR A POSTPARTUM FOLLOW-UP OF A GDM, WHICH WAS DIAGNOSED SHORTLY BEFORE DELIVERY AT 36TH WEEK OF GESTATION, DUE TO FETAL DISTRESS. SHE RECEIVED METFORMIN ASSOCIATED WITH BASAL INSULIN THERAPY. SUBSEQUENTLY SHE CONVERTED TO BASAL BOLUS INSULIN THERAPY. RECENTLY, THE PATIENT PRESENTED WITH POOR METABOLIC CONTROL (11.5% H BA1C) AND HAS DEVELOPED DIABETIC PAPILLOPATHY. THE SPECIFIC PHENOTYPIC FEATURES AND THE MANAGEMENT OF LATENT AUTOIMMUNE DIABETES IN ADULTS ARE CHALLENGING AND FURTHER RESEARCH SHOULD BE PERFORMED.
Keywords
GESTATIONAL DIABETES MELITUS LATENT AUTOIMMUN E DIABETES OF ADULTHOOD DIABETIC PAPILLOPATHY INSULIN THERAPY
Full Text
The body of this article is intentionally hidden on the public page. Please use the PDF reader or the PDF download for the complete text.
References
[1]
Luz Yolanda Toro Suarez, “International Textbook of Diabetes Mellitus, 4th edition,” pp. 1 –27, 2015.
[2]
American Diabete s Association “STANDARDS OF MEDICAL CARE IN DIABETES — 2021 American Diabetes Associa tion Medical Care in Diab etes 2021,” Diabetes Care vol. 44, Suppl. 1 January, 2021.
[3]
E. C. Johns, F. C. Denison, J. E. Norman, and R. M. Reynolds, “Gestational Diabetes Mel litus: Mechanisms, Treatment, and Complications,” Trends in Endocrinology and Metabolism. 2018.
[4]
A. Lapolla, M. G. Dalfrà, and D. Fedele, “Diabetes related autoimmunity in gestational diabetes mellitus: Is it important?,” Nutr. Metab. Cardiovasc. Dis., vol. 19, no. 9, pp. 674–682, 2009.
[5]
M. Incani, M. G. Baroni, and E. Cossu, “Testing for ty pe 1 diabetes autoantibod ies in gestational diabetes mellitus (GDM): Is it clinically useful?,” BMC Endocr. Disord., vol. 19, no. 1, pp. 1–6, 2019.
[6]
A. Kumar, A. De Leiva, and R. Corcoy, “Autoimmunity in Gestational Diabetes Mellitus,” Front. Diabetes, vol. 28, pp. 234–242, 2019.
[7]
H. Wucher, J. Lepercq, and J. Timsit, “Onset of autoimmune type 1 diabetes during pregnancy: Prevalence and out comes,” Best Pract. Res. Clin. Endoc rinol. Metab. , vol. 24, no. 4, pp. 617 –624, 2010.
[8]
R. Buzzetti et al., “Management of latent autoimmune diabete s in adults: A consensus statement from an international expert panel,” Diabetes, vol. 69, no. 10, pp. 2037–2047, 2020.
[9]
P. Gill, J. Piris, and B. F. Warren, “Lesson of the month,” Histopathology, vol. 42, no. 1, pp. 88 –90, 2003.
[10]
Flavius-Cristian M ărcău, Sorin Purec, George Niculescu , „ Study on the refusal of vaccination against Covid-19 in Romania” în Vaccines 2022, 10, 261.https://doi.org/10.3390/vaccines10020261.
[11]
L. Fadiga, J. Saraiva, D. C atarino, J. Frade, M. Melo, and I. Paiva , “Adult -onset autoimmune diabetes: comparative analysis of classical and latent presentation,” Diabetol. Metab. Syndr., vol. 12, no. 1, pp. 1–9, 2020.
[12]
C. NILSSON, “Gestational Diabetes Mellit us Predicts,” Diabetes Care, vol. 30, no. 8, p. 19681970, 2007.
[13]
Y. Xiang et al., “Glutamic acid decarboxylase a utoantibodies are dominant but insufficient to identify most Chinese with adult-onset non-insulin requiring autoimmune diabetes: LADA China study 5,” Acta Diabetol., vol. 52, no. 6, pp. 1121–1127, 2015.
[14]
A. O. Y. Luk et al., “Diabetes-related complications and mortality in patients with young -onset latent autoimmune diabetes: A 14 -year analysis of the prospective Hong Kong Diabetes register,” Diabetes Care, vol. 42, no. 6, pp. 1042–1050, 2019.
[15]
L. C. Stene et al ., “Normal but increasing hemoglobin A 1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY),” Pediatr. Diabetes, vol. 7, no. 5, pp. 247–253, 2006.